ERBB2 and breast cancer: In fact, HER2 gene amplification is associated with a higher invasiveness and metastatic potential, but despite HER2’s prognostic role remaining controversial, therapy with trastuzumab and lapatinib (an orally active drug for breast cancer and other solid tumours) was found to improve outcome in a subset of cases [5].